Core Viewpoint - The overall trend of acute respiratory infectious diseases in China is currently declining, as reported by the Chinese Center for Disease Control and Prevention (CDC) [1]. Group 1: Current Situation of Respiratory Diseases - The CDC is continuously monitoring flu-like cases and severe acute respiratory infection cases in hospitals across the country [1]. - The positive detection rates for respiratory samples in sentinel hospitals show that the top three pathogens are influenza virus, respiratory syncytial virus, and rhinovirus, all of which are known common pathogens [1]. - There have been no discoveries of unknown pathogens or new infectious diseases related to these respiratory infections [1]. Group 2: Flu Trends and Statistics - The current flu epidemic in China is at a low level, with a continuous decline over the past two months [1]. - The positive detection rate of influenza virus, the number of reported cases, and the number of reported outbreaks are all on a downward trend [1]. - The predominant circulating strain is the H3N2 subtype of influenza A, while the proportion of the Victoria lineage of influenza B has shown a slight increase [1]. Group 3: Other Respiratory Pathogens - The positive detection rate for respiratory syncytial virus is also declining, with higher rates observed in northern provinces compared to southern provinces [1]. - The positive detection rate for rhinovirus is fluctuating at a certain level [1]. - The detection rates for other monitored respiratory pathogens, including the novel coronavirus, remain low overall [1].

Investment Rating - The report maintains a "Recommendation" rating for the company with a target price of 29 yuan [2][8]. Core Views - The company's performance is under pressure in the short term, with a significant decline in revenue and profit. The total revenue for the first half of 2025 was 1.246 billion yuan, down 20.92%, and the net profit attributable to shareholders was 189 million yuan, down 46.82% [2][3]. - The company is making steady progress in expanding its overseas business, which is expected to help mitigate domestic market challenges [2][8]. Financial Summary - **Revenue and Profit Forecasts**: The projected total revenue for 2025 is 2.634 billion yuan, reflecting a year-on-year decrease of 14.1%. The net profit attributable to shareholders is expected to be 418 million yuan, down 25.5% [4][9]. - **Earnings Per Share (EPS)**: The EPS for 2025 is forecasted at 0.89 yuan, with a price-to-earnings (P/E) ratio of 24 [4][9]. - **Market Capitalization**: The total market capitalization of the company is approximately 9.956 billion yuan [5]. Business Segment Performance - **Chronic Disease Management Testing**: Revenue for this segment was 563 million yuan, down 26.06%. The company is responding to domestic market pressures by launching new products and enhancing its service model [8]. - **Infectious Disease Testing**: Revenue decreased to 379 million yuan, down 21.14%. The company is focusing on maintaining its market position while expanding its product offerings in overseas markets [8]. - **Drug Abuse Testing**: This segment showed a stable growth with revenue of 145 million yuan, up 4.26%, driven by e-commerce strategies [8]. - **Prenatal and Genetic Testing**: Revenue was 138 million yuan, down 11.67%, as the company focuses on product innovation to adapt to market changes [8]. Investment Recommendations - The report suggests that considering the domestic demand for products, the pace of international expansion, and stock compensation expenses, the net profit attributable to shareholders is expected to be 4.2 billion yuan, 4.9 billion yuan, and 5.9 billion yuan for 2025, 2026, and 2027 respectively [8].